about
The ciliary neurotrophic factor and its receptor, CNTFR alphaSynthesis, conformational analysis and antidepressant activity of moclobemide new analoguesThe study of shea butter. 4. Stability of medicaments in shea butter ointments and creams5-Lipoxygenase: enzyme expression and regulation of activityThe study of shea butter. 3. Comparative assessment of antioxidants and release of medicamentsThe absolute configuration of (+)-6'-hydroxymethyllaudanosine and the optical purity of its 3-phenylisochromane derivativesSynthesis, antibacterial, antifungal and anti-HIV evaluation of Schiff and Mannich bases of isatin derivatives with 3-amino-2-methylmercapto quinazolin-4(3H)-oneSimultaneous determination of prostaglandins (PG) E2, A2 and B2 and stability studies of PGE2 in pharmaceutical preparations by ion-pair reversed phase HPLCComputer system validation: an overview of official requirements and standards.Lipoprotein-mimicking biovectorized systems for methotrexate delivery.Relations between compaction data for some crystalline pharmaceutical materials.[Rheological studies on ointment bases. 3. Electron microscope study of a thixotropic gel of peanut oil and Aerosil].[Purification, glucose-6-phosphate dehydrogenase inhibition, and HPLC analysis of four 1,8-dihydroxyanthrones]Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics.Development of an abdominal magnetic resonance (MR) contrast agent formulation with Oral Magnetic Particles (OMP, Ferristene).How accurate is the determination of the relative bioavailability of transdermal drug formulations from pharmacodynamic response data?Peptides and polypeptides as modulators of the immune response: thymopentin--an example with unknown mode of action.Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist.CI-1017, a functionally M1-selective muscarinic agonist: design, synthesis, and preclinical pharmacology.Alpha 1-adrenoreceptor antagonists bearing a quinazoline or a benzodioxane moiety.Pharmacological receptors: a century of discovery--and more.Cholinergic receptors and neurodegenerative diseases.Nicotinic systems in central nervous systems disease: degenerative disorders and beyond.Central nicotinic receptor ligands and pharmacophores.Receptors in neurodegenerative diseases, muscarinic cholinergic receptors.Ligands for the common allosteric site of acetylcholine M2-receptors: development and application.Receptors in cardiovascular disease: review and introduction.The alpha 1a and alpha 1b-adrenergic receptor subtypes: molecular mechanisms of receptor activation and of drug action.Selection, design and evaluation of new radioligands for PET studies of cardiac adrenoceptors.Enigmatic receptors.Imidazoline receptors: a challenge.Sigma receptors: recent advances and new clinical potentials.Excitatory amino acid agonists and antagonists: pharmacology and therapeutic applications.Metabotropic glutamate receptors: a structural view point.Synthesis and pharmacological properties of novel glycine antagonists.Receptors in neurodegenerative diseases.Neurotrophin receptor structure and interactions.The RET receptor tyrosine kinase: activation, signalling and significance in neural development and disease.Rediscovering good old friend IGF-I in the new millenium: possible usefulness in Alzheimer's disease and stroke.Apoptosis induced by death receptors.
P1433
Q28144474-10882D4C-E179-4F82-92F8-4D8060B73297Q28235695-D4E6795F-57DB-426A-A09F-94F7C0405690Q28237979-0ADD041C-78E7-4F28-8C20-EBAB0B19D4D4Q28239479-A15D8000-861E-45FF-AAA5-EABE49C47CCCQ28243556-452DD0FC-C914-47F0-B121-2DFA43FA1365Q28334146-FDC9A083-4170-4701-ACBA-8BB93849AB4BQ28375289-9DCD7D45-89AD-45F2-A6B5-AB32DC542C1DQ28622184-CC677815-F4AD-409D-9184-F8DFCD218242Q30430238-AFE01124-686F-4AC3-8906-817AC1B32FCCQ30580559-8F1B66D7-B0CF-4736-80A5-F65566EDBCE7Q30623438-7BD25BB7-17D8-44E7-A9D3-25ABE9BA4BF6Q30737803-DE49359D-73AC-4BD3-A5FB-38892AEAB83AQ31095905-34297115-EF91-4CFC-B988-8410857D3A11Q31374188-04E9978E-021E-4F0D-8AFD-C10D3D4A8643Q31949409-BCC2C68C-87DC-4F61-A63A-E4400A71133FQ32037843-E53308EC-E877-4CF9-85BA-D6FC916B4D2FQ33708972-E03BFFAA-52AD-4E9A-B59D-70753A71CEE6Q33902026-0FE03E66-D07B-4B4A-B855-6A28EBD7D89CQ33902030-B5017027-92F1-4BF3-B5FB-18766785BDFCQ33902035-AA2ADE2E-123D-4AB4-849B-12BD5D9A3F8EQ33919785-61932817-B8DC-4562-B1DB-4097FFDC1839Q33919789-BE4F42F8-1C11-492B-9863-A401C78386EBQ33919793-65EAAA44-48FD-4E92-A95C-47ABEE001D2BQ33919798-51BA7BD0-6C57-4E52-897C-E48EEC8DE916Q33919803-96896EAC-30CF-448A-9219-C2EDD0FB4B15Q33919808-97373395-004B-4258-B830-662BDB309A0BQ33919813-280FBE98-0436-499E-81A9-4F9BE00D0F2CQ33919818-47B6BE30-BBF2-4966-8452-90C8139FFB2DQ33919826-38F8FCA2-9A2C-4BDF-A4D5-19E3BA9AAF79Q33919831-9E568A21-7BBE-4555-BB27-F088ECD2E4BEQ33919834-A935F4A7-B2B7-4C65-B9BA-3D81F5B7432FQ33919837-B53EDF2F-21C4-49C4-A53F-D64DB2B3B04CQ33919841-D82D0382-A534-4A11-93BE-E573B552C53DQ33919846-42224B08-928D-4056-A540-E925E0E90A72Q33919851-075FA0CD-AB92-4B7E-A11B-BF3D2B677A39Q33919854-4E7C9D0C-F1EB-4FAE-B45D-5B51EF944856Q33919859-B2B163C4-8238-41DC-8031-6E1A728DEE31Q33919864-52515990-34E9-49A7-92B4-ACD0D6E6A492Q33919869-DBBC7556-2386-48CE-86FB-714BD3492658Q33919873-C60A2F6B-684B-4E0B-BED2-384542E48FD6
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
wetenschappelijk tijdschrift van Elsevier
@nl
wissenschaftliche Fachzeitschrift
@de
name
Pharmaceutica acta Helvetiae
@ast
Pharmaceutica acta Helvetiae
@en
Pharmaceutica acta Helvetiae
@es
Pharmaceutica acta Helvetiae
@it
Pharmaceutica acta Helvetiae
@nl
type
label
Pharmaceutica acta Helvetiae
@ast
Pharmaceutica acta Helvetiae
@en
Pharmaceutica acta Helvetiae
@es
Pharmaceutica acta Helvetiae
@it
Pharmaceutica acta Helvetiae
@nl
altLabel
Pharm Acta Helv
@en
prefLabel
Pharmaceutica acta Helvetiae
@ast
Pharmaceutica acta Helvetiae
@en
Pharmaceutica acta Helvetiae
@es
Pharmaceutica acta Helvetiae
@it
Pharmaceutica acta Helvetiae
@nl
P3181
P1055
P1156
P123
P1476
Pharmaceutica acta Helvetiae
@en